Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 8/20 | 0.34 |
| ▸ | CASP1 | P29466 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16168238 | 0.79 | CASP1 (0.40) | CASP1 | |
| SCHEMBL18133071 | 0.76 | BMP1 (0.48) | CASP1 | |
| SCHEMBL1262565 | 0.75 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL1690906 | 0.75 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL18428122 | 0.75 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL21732968 | 0.74 | GNPAT (0.35) | CASP1 | |
| SCHEMBL16168241 | 0.72 | MME (0.39) | CASP1 | |
| SCHEMBL30797870 | 0.70 | CTSS (0.49) | CTSKCTSSCTSLCTSB | |
| SCHEMBL30797986 | 0.70 | CTSS (0.49) | CTSKCTSSCTSLCTSB | |
| SCHEMBL29946263 | 0.70 | CASP1 (0.47) | CTSKCTSSCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | THE UNIVERSITY OF WYOMING | 2012-06-14 | — | — | US | disclosed |
| US-8105570-B2 | Covalently bond to polymer or other moiety that blocks activity until reaching delivery site; not easily circumventable | THE UNIVERSITY OF WYOMING (US) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | OPRK1, OPRM1, AANAT | CTSK 2540/4885APLNR 3265/4885CTSS 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.